Research Article
Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer
Table 1
Clinicopathologic characteristics, demographics, and values for 838 EOC patients.
| | Age (years) | Median: 55; range: 21–79 | | BMI (kg/m2) | Median: 23; range: 15–47 | | Menopausal status | | | Yes | 505 (60.3%) | | No | 333 (39.7%) | | Histology | | | Serous | 599 (71.5%) | | Mucous and others | 231 (28.5%) | | Differentiation | | | | 420 (50.1%) | | | 418 (49.9%) | | FIGO stage (2009) | | | I-II | 243 (29.0%) | | III-IV | 595 (71.0%) | | With lymphadenectomy | 631 (75.2%) | | Pelvic | 527 (83.5%) | | Para-aortic + pelvic | 104 (16.5%) | | Removed lymph nodes | Median: 25; range: 12–57 | | Lymph nodes metastasis | | | No | 642 (76.6%) | | Yes | 196 (23.4%) | | Residual disease | | | <1 cm | 631 (75.3%) | | ≥1 cm | 207 (24.7%) | | Ascites volume (mL) | Median: 1000; range: 0–7000 | | ≤1000 | 591 (70.5%) | | >1000 | 247 (29.5%) | | Serum CA125 (U/mL) | Median: 675; range: 23–7400 | | ≤675 | 521 (62.2%) | | >675 | 317 (37.8%) | | Tumor-stroma ratio (TSR) | | | Stroma-poor (TSR < 50%) | 575 (68.6%) | | Stroma-rich (TSR ≥ 50%) | 263 (31.4%) |
|
|
